why choose us

First received: July 14, 2023

Clinical Trial: Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia

Study Status: Completed

Recruit Status: RECRUITING

Condition: Chronic Lymphocytic Leukemia

Study Type: INTERVENTIONAL


Official Title: Addition of loNcasTuxImab teSirine to AcalabruTinib in Chronic Lymphocytic Leukemia(Anti-Static Study)

Brief Summary: Study is a phase I study to determine the maximum tolerated dose of adding Loncastuximab Tesirine to Aclabrutinib in the treatment of chronic lymphocytic leukemia.

Read more